These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 30280720)

  • 1. [Epidemiology of invasive pneumococcal disease in Tarragona, Spain, 2012-2015: incidence, lethality and serotype-coverage for distinct antipneumococcal vaccine formulations].
    Vila Córcoles Á; Dacosta Moreira C; de Diego Cabanes C; Ochoa Gondar O; Raga Gutiérrez M; Gómez Bertomeu F; Raga Luria X; Figuerola Massana E
    Rev Esp Salud Publica; 2018 Oct; 92():. PubMed ID: 30280720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term effect of pneumococcal conjugate vaccines on invasive pneumococcal disease incidence among people of all ages from national, active, laboratory-based surveillance in South Africa, 2005-19: a cohort observational study.
    von Gottberg A; Kleynhans J; de Gouveia L; Tempia S; Meiring S; Quan V; du Plessis M; von Mollendorf C; Crowther-Gibson P; Avenant T; du Plessis N; Kularatne R; Chibabhai V; Madhi SA; Klugman KP; Whitney CG; Cohen C;
    Lancet Glob Health; 2024 Sep; 12(9):e1470-e1484. PubMed ID: 39151982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccine preventable diseases and vaccination coverage in Aboriginal and Torres Strait Islander people, Australia 2006-2010.
    Naidu L; Chiu C; Habig A; Lowbridge C; Jayasinghe S; Wang H; McIntyre P; Menzies R
    Commun Dis Intell Q Rep; 2013 Dec; 37 Suppl():S1-95. PubMed ID: 24410428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fractional Doses of Pneumococcal Conjugate Vaccine - A Noninferiority Trial.
    Gallagher KE; Lucinde R; Bottomley C; Kaniu M; Suaad B; Mutahi M; Mwalekwa L; Ragab S; Twi-Yeboah L; Berkley JA; Hamaluba M; Karani A; Shangala J; Otiende M; Gardiner E; Mugo D; Smith PG; Tabu C; Were F; Goldblatt D; Scott JAG
    N Engl J Med; 2024 Nov; 391(21):2003-2013. PubMed ID: 39330966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of a Reduced PCV10 Dose Schedule on Pneumococcal Carriage in Vietnam.
    Yoshida LM; Toizumi M; Nguyen HAT; Quilty BJ; Lien LT; Hoang LH; Iwasaki C; Takegata M; Kitamura N; Nation ML; Hinds J; van Zandvoort K; Ortika BD; Dunne EM; Satzke C; Do HT; Mulholland K; Flasche S; Dang DA
    N Engl J Med; 2024 Nov; 391(21):1992-2002. PubMed ID: 39602629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Invasive pneumococcal disease in Australia, 2006.
    Roche PW; Krause V; Cook H; Barralet J; Coleman D; Sweeny A; Fielding J; Giele C; Gilmour R; Holland R; Kampen R; ; Brown M; Gilbert L; Hogg G; Murphy D;
    Commun Dis Intell Q Rep; 2008 Mar; 32(1):18-30. PubMed ID: 18522302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High prevalence of 19A pneumococcal serotype carriage during the COVID-19 pandemic in Brazil.
    Primon-Barros M; Varela FH; Polese-Bonatto M; Sartor ITS; Azevedo TR; de David CN; Tonini ML; Stein RT; Scotta MC; Dias CAG
    Braz J Infect Dis; 2024; 28(6):104467. PubMed ID: 39577042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of
    Che J; Bai P; Xu J; Shao Z
    Hum Vaccin Immunother; 2024 Dec; 20(1):2416763. PubMed ID: 39631045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changing epidemiology of invasive pneumococcal disease in Australian children after introduction of a 7-valent pneumococcal conjugate vaccine.
    Williams SR; Mernagh PJ; Lee MH; Tan JT
    Med J Aust; 2011 Feb; 194(3):116-20. PubMed ID: 21299484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population immunity to pneumococcal serotypes in Kilifi, Kenya, before and 6 years after the introduction of PCV10 with a catch-up campaign: an observational study of cross-sectional serosurveys.
    Gallagher KE; Adetifa IMO; Mburu C; Bottomley C; Akech D; Karani A; Pearce E; Wang Y; Kagucia EW; Goldblatt D; Hammitt LL; Scott JAG
    Lancet Infect Dis; 2023 Nov; 23(11):1291-1301. PubMed ID: 37429307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of 10-valent pneumococcal conjugate vaccine on trends of pneumococcal meningitis in children under five years, Uganda, 2003-2022.
    Nuwamanya Y; Ampeire I; Baganizi M; Atugonza R; Nsubuga F; Kwesiga B; Migisha R; Bulage L; Kadobera D; Ario AR; Kisakye A
    BMC Infect Dis; 2024 Oct; 24(1):1187. PubMed ID: 39434021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding healthcare providers' preferred attributes of pediatric pneumococcal conjugate vaccines in the United States.
    Mohanty S; Tsai JH; Ning N; Martinez A; Verma RP; Heisen M; Weaver J; Feemster KA; Chun B; Weiss TW; Schmier JK
    Hum Vaccin Immunother; 2024 Dec; 20(1):2325745. PubMed ID: 38566496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Invasive pneumococcal disease in Indigenous people in north Queensland: an update, 2005-2007.
    Hanna JN; Humphreys JL; Murphy DM
    Med J Aust; 2008 Jul; 189(1):43-6. PubMed ID: 18601643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Invasive pneumococcal disease in Australia, 2005.
    Roche P; Krause V; Cook H; Bartlett M; Coleman D; Davis C; Fielding J; Giele C; Gilmour R; Holland R; Kampen R;
    Commun Dis Intell Q Rep; 2007 Mar; 31(1):86-100. PubMed ID: 17503648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. General health, otitis media, nasopharyngeal carriage and middle ear microbiology in Northern Territory Aboriginal children vaccinated during consecutive periods of 10-valent or 13-valent pneumococcal conjugate vaccines.
    Leach AJ; Wigger C; Beissbarth J; Woltring D; Andrews R; Chatfield MD; Smith-Vaughan H; Morris PS
    Int J Pediatr Otorhinolaryngol; 2016 Jul; 86():224-32. PubMed ID: 27260611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre- & post-vaccine trends in pneumococcal serotypes & antimicrobial resistance patterns.
    Peela SCM; Sistla S; Nagaraj G; Govindan V; Kadahalli RKL
    Indian J Med Res; 2024 Sep&Oct; 160(3&4):354-361. PubMed ID: 39632638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.
    Lee CC; Chen CW; Yen HK; Lin YP; Lai CY; Wang JL; Groot OQ; Janssen SJ; Schwab JH; Hsu FM; Lin WH
    Clin Orthop Relat Res; 2024 Dec; 482(12):2193-2208. PubMed ID: 39051924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic characterization and estimated 4CMenB vaccine strain coverage of 284
    Efron A; Brozzi A; Biolchi A; Bodini M; Giuliani M; Guidotti S; Lorenzo F; Moscoloni MA; Muzzi A; Nocita F; Pizza M; Rappuoli R; Tomei S; Vidal G; Vizzotti C; Campos J; Sorhouet Pereira C
    Hum Vaccin Immunother; 2024 Dec; 20(1):2378537. PubMed ID: 39037011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimating pneumococcal carriage dynamics in adults living with HIV in a mature infant pneumococcal conjugate vaccine programme in Malawi, a modelling study.
    Phiri J; Sibale L; Mlongoti L; Mitole N; Kusakala A; Khwiya M; Kayembe T; Lisimba E; Kapwata P; Malisita K; Chaguza C; Ferreira DM; Thindwa D; Jambo K
    BMC Med; 2024 Sep; 22(1):419. PubMed ID: 39334289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccine preventable diseases and vaccination coverage in Aboriginal and Torres Strait Islander people, Australia 2003 to 2006.
    Menzies R; Turnour C; Chiu C; McIntyre P
    Commun Dis Intell Q Rep; 2008 Jun; 32 Suppl():S2-67. PubMed ID: 18711998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.